Clinical Trials Browser

OTHER × Bevacizumab × CNS × Clear all

NCT07449481 2026-03-04

A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Phase 2 Not yet recruiting

Brain Neoplasms

NCT06663306 2026-03-02

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT06888817 2026-02-25

BRAINS

Phase 3 Recruiting

Brain Neoplasms, Glioma, Radiation Injuries

NCT01356290 2026-02-23

MEMMAT

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

NCT02669173 2026-02-23

Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Recurrence

NCT06955169 2026-02-17

MOMENTUM-1

Phase 2 Recruiting

Meningioma

NCT07263438 2026-02-13

Phenix

Phase 2 Recruiting

Glioblastoma, Recurrence

NCT07346157 2026-01-16

PNOC044

Phase 1/2 Not yet recruiting

Medulloblastoma

NCT05871021 2026-01-09

PRIDE

Phase 2 Recruiting

Glioblastoma

NCT03743662 2026-01-07

Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

Phase 2 Active not recruiting

Glioblastoma

NCT05956821 2025-12-08

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Phase 1/2 Recruiting

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Oligodendroglioma

NCT03532295 2025-11-21

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Phase 2 Completed

51 enrolled 16 charts

Glioblastoma, Glioma

NCT03175432 2025-11-03

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1 Active not recruiting

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT01951482 2025-08-17

Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer

Phase 3 Completed

Brain Neoplasms

NCT04074785 2025-08-17

SCCC-06319

Phase EARLY_PHASE1 Terminated

Brain Neoplasms, Glioblastoma

NCT06471465 2025-08-17

BRADI

Phase 3 Recruiting

Brain Neoplasms

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03698162 2025-08-05

Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases

Phase NA Terminated

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03890952 2025-07-24

Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

Phase 2 Completed

Brain Neoplasms

NCT06401824 2025-05-06

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Phase 2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01083966 2025-04-09

Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma

Phase 1 Suspended

Brain Neoplasms, Neurilemmoma, Neuroma, Neuroma, Acoustic

NCT01269853 2025-04-09

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

Phase 1/2 Recruiting

Astrocytoma, Glioblastoma, Neoplasms

NCT01386710 2025-04-09

Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

Phase 1/2 Suspended

Astrocytoma, Glioblastoma, Neoplasms

NCT03452579 2025-02-28

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

Phase 2 Active not recruiting

90 enrolled 16 charts

Glioblastoma

NCT01894061 2025-02-17

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

Phase 2 Completed

25 enrolled 16 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT06812871 2025-02-06

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Phase 2 Recruiting

Meningeal Carcinomatosis

NCT06801730 2025-01-30

NALIRIBVRG

Phase 2 Recruiting

Glioma, Recurrence

NCT01814813 2025-01-24

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Phase 2 Terminated

90 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01743950 2025-01-08

A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

Phase 2 Terminated

Glioblastoma, Glioma

NCT06728865 2024-12-11

Better Brain

Phase 2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05807893 2024-11-13

SUPER BRAIN

Phase 2/3 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04952571 2024-10-15

Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)

Phase 2 Terminated

Glioblastoma

NCT01149850 2024-09-19

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Phase 2 Completed

Glioblastoma, Gliosarcoma

NCT03661723 2024-09-19

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Phase 2 Completed

60 enrolled 23 charts

Glioblastoma

NCT05271240 2024-09-19

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

Phase 3 Recruiting

Brain Neoplasms, Glioblastoma, Glioma

NCT01837862 2024-07-05

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Phase 1/2 Completed

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma, Gliosarcoma, Optic Nerve Glioma

NCT05638451 2024-06-05

Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients

Phase 2 Unknown

Glioblastoma

NCT02308527 2024-05-14

BEACON

Phase 2 Active not recruiting

Neuroblastoma

NCT05685836 2024-03-20

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Neuroma, Acoustic, Neurofibromatosis 2

NCT01811498 2024-01-30

Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM

Phase 1/2 Completed

31 enrolled 7 charts

Brain Neoplasms, Glioblastoma

NCT06210438 2024-01-18

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

Phase 2 Not yet recruiting

Brain Neoplasms

NCT02833701 2023-10-24

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

Phase 1 Terminated

Glioblastoma, Glioma

NCT02313272 2023-10-23

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

Phase 1 Completed

32 enrolled 12 charts

Glioma, Neoplasms, Neurologic Manifestations

NCT05540275 2023-10-06

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Phase 2 Not yet recruiting

Glioblastoma

NCT02386826 2023-09-21

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Phase 1 Completed

CNSGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Glioblastoma, Colorectal Neoplasms, Gliosarcoma

NCT04345146 2023-08-28

Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC

Phase 2 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05718466 2023-07-17

Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy

Phase 3 Completed

35 enrolled 13 charts

Glioblastoma, Recurrence

NCT00876993 2023-07-03

Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors

Phase 1 Completed

26 enrolled 16 charts

Central Nervous System Neoplasms

NCT03032484 2023-06-15

TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

Phase 2 Completed

25 enrolled 9 charts

Astrocytoma